Corbus Pharmaceuticals Holdings, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on October 15, 2026, to furnish an updated investor presentation. The filing details the company’s corporate presentation, which outlines the status of its clinical programs and corporate milestones.
The presentation highlights the company’s pipeline, which includes CRB-701, a next-generation Nectin-4 antibody-drug conjugate (ADC), and CRB-913, a peripherally restricted CB1 inverse agonist for obesity. Regarding CRB-701, the company reported that a Phase 1/2 study in second-line oropharyngeal squamous cell carcinoma (OPSCC) demonstrated a confirmed objective response rate (cORR) of 43% at a dose of 3.6 mg/kg. A registrational study, named TEMPO-1, is currently underway.
For CRB-913, the presentation notes that a Phase 1b study in obesity showed a placebo-adjusted weight loss of 5% at 12 weeks. The company anticipates initiating a Phase 2 monotherapy study in the first half of 2027. The filing also discloses that the company had $118 million in cash, cash equivalents, and investments as of June 30, 2026.
The document lists the company’s senior management team, including Chief Executive Officer Yuval Cohen, Chief Financial Officer Sean Moran, and Chief Operating Officer Ian Hodgson. It also details the members of the Board of Directors, including Winston Kung, Anne Altmeyer, and John K. Jenkins.
